What Do Patients Know about Biosimilar Drugs?

It’s also likely that the results may be biased because, like many online surveys, it’s an unknown population, noted Dr. Caleb Alexander, co-director of the Johns Hopkins Center for Drug Safety and Effectiveness in Baltimore.

Even so, the findings highlight the need for more patient education about biosimilars, Alexander, who wasn’t involved in the study, said by email.

“Some patients may rightly have questions and concerns about biosimilar products – this is understandable and it is important that clinicians and health systems and other stakeholders work to address these questions and ensure that any misconceptions about these products are addressed,” Alexander said.

Reference

1. Peyrin-Biroulet L, Lönnfors S, Roblin X, et al. Patient perspectives on biosimilars: A survey by the European Federation of Crohn’s and Ulcerative Colitis Associations. J Crohns Colitis. 2016 Jul 31. pii: jjw138. [Epub ahead of print]